<DOC>
	<DOCNO>NCT00295061</DOCNO>
	<brief_summary>The purpose clinical study ( ChAMP - Comparability pharmacokinetics Alpha-1 Modified Process ) compare pharmacokinetic , safety tolerability Alpha-1 Proteinase Inhibitor ( Human ) , modify process ( Alpha-1 MP ) Prolastin adult Alpha1-antitrypsin deficient patient . Patients infuse intravenously study drug weekly schedule 24 week .</brief_summary>
	<brief_title>Comparison Pharmacokinetic , Safety , Tolerability Alpha-1 MP Prolastin In Alpha1-antitrypsin Deficient Adults</brief_title>
	<detailed_description>The objective study demonstrate pharmacokinetic comparability Alpha-1 MP Prolastin® subject Alpha1-antitrypsin deficiency . This study divide three 8-week treatment sequence include initial 8-week double-blind treatment period ( one 2 study drug ) , second 8-week double-blind treatment period ( study drug ) , third 8-week open-label treatment period ( Alpha-1 MP ) .</detailed_description>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Documented diagnosis congenital Alpha1antitrypsin deficiency Must receive augmentation therapy plasmaderived ( human ) Alpha1Proteinase Inhibitor ( Prolastin® ) least one month prior study entry . Signed write informed consent prior initiation study relate procedure Females pregnant , breast feeding , childbearing potential , unwilling practice adequate contraception throughout study Use systemic steroid within 2 week prior receive study treatment ( include use inhaled steroid use routine need basis ) . Subjects exacerbation disease within one month trial entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>alpha 1-Antitrypsin Deficiency</keyword>
	<keyword>alpha 1-Antitrypsin</keyword>
	<keyword>pulmonary emphysema</keyword>
</DOC>